Cadre (CDRE) Competitors $32.77 +0.06 (+0.18%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$32.76 -0.02 (-0.05%) As of 07/11/2025 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CDRE vs. BLCO, NARI, IRTC, TMDX, SLNO, INSP, NVST, PRCT, LIVN, and WRBYShould you be buying Cadre stock or one of its competitors? The main competitors of Cadre include Bausch + Lomb (BLCO), Inari Medical (NARI), iRhythm Technologies (IRTC), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Inspire Medical Systems (INSP), Envista (NVST), PROCEPT BioRobotics (PRCT), LivaNova (LIVN), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry. Cadre vs. Its Competitors Bausch + Lomb Inari Medical iRhythm Technologies TransMedics Group Soleno Therapeutics Inspire Medical Systems Envista PROCEPT BioRobotics LivaNova Warby Parker Bausch + Lomb (NYSE:BLCO) and Cadre (NYSE:CDRE) are both medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership. Is BLCO or CDRE more profitable? Cadre has a net margin of 6.87% compared to Bausch + Lomb's net margin of -7.50%. Cadre's return on equity of 12.52% beat Bausch + Lomb's return on equity.Company Net Margins Return on Equity Return on Assets Bausch + Lomb-7.50% 2.62% 1.28% Cadre 6.87%12.52%6.04% Does the media favor BLCO or CDRE? In the previous week, Bausch + Lomb had 3 more articles in the media than Cadre. MarketBeat recorded 5 mentions for Bausch + Lomb and 2 mentions for Cadre. Bausch + Lomb's average media sentiment score of 1.02 beat Cadre's score of 0.36 indicating that Bausch + Lomb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cadre 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, BLCO or CDRE? Bausch + Lomb has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Cadre has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Which has better earnings & valuation, BLCO or CDRE? Cadre has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBausch + Lomb$4.79B1.02-$317M-$1.03-13.48Cadre$567.56M2.35$36.13M$0.9534.49 Do insiders & institutionals have more ownership in BLCO or CDRE? 11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 44.0% of Cadre shares are owned by institutional investors. 0.8% of Bausch + Lomb shares are owned by insiders. Comparatively, 37.0% of Cadre shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate BLCO or CDRE? Bausch + Lomb currently has a consensus price target of $15.45, indicating a potential upside of 11.34%. Cadre has a consensus price target of $37.50, indicating a potential upside of 14.43%. Given Cadre's stronger consensus rating and higher possible upside, analysts clearly believe Cadre is more favorable than Bausch + Lomb.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch + Lomb 1 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.17Cadre 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryCadre beats Bausch + Lomb on 12 of the 16 factors compared between the two stocks. Get Cadre News Delivered to You Automatically Sign up to receive the latest news and ratings for CDRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDRE vs. The Competition Export to ExcelMetricCadrePROTECTION IndustryIndustrials SectorNYSE ExchangeMarket Cap$1.33B$2.04B$7.55B$20.73BDividend Yield1.16%1.82%4.52%3.71%P/E Ratio34.5039.1025.1527.84Price / Sales2.353.68117.6342.34Price / Cash23.0960.9027.4522.63Price / Book4.279.514.404.57Net Income$36.13M$110.42M$791.63M$989.30M7 Day Performance1.71%-0.71%0.74%0.20%1 Month Performance-9.43%-0.56%4.85%3.95%1 Year Performance-10.98%199.07%28.11%10.27% Cadre Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDRECadre2.99 of 5 stars$32.77+0.2%$37.50+14.4%-7.3%$1.33B$567.56M34.502,284BLCOBausch + Lomb3.1044 of 5 stars$13.83-0.4%$15.54+12.4%-12.7%$4.91B$4.79B-13.4313,500Analyst ForecastNARIInari Medical0.2738 of 5 stars$79.97flat$69.22-13.4%N/A$4.68B$493.63M-59.24800News CoverageIRTCiRhythm Technologies1.0471 of 5 stars$139.22-2.3%$138.60-0.4%+39.7%$4.55B$591.84M-44.342,000TMDXTransMedics Group2.2237 of 5 stars$125.17-3.1%$127.33+1.7%-21.9%$4.37B$441.54M92.04210News CoveragePositive NewsAnalyst RevisionSLNOSoleno Therapeutics4.6253 of 5 stars$85.27-1.6%$107.10+25.6%+83.3%$4.37BN/A-18.4630Trending NewsAnalyst ForecastINSPInspire Medical Systems4.911 of 5 stars$127.11-1.1%$211.91+66.7%-3.8%$3.79B$802.80M58.581,246News CoveragePositive NewsAnalyst UpgradeNVSTEnvista3.2645 of 5 stars$19.66-3.6%$20.23+2.9%+20.7%$3.46B$2.51B-3.0112,300Analyst ForecastPRCTPROCEPT BioRobotics2.3175 of 5 stars$56.97-1.6%$90.00+58.0%-17.1%$3.20B$249.12M-33.51430News CoverageAnalyst ForecastLIVNLivaNova3.1681 of 5 stars$45.58-1.2%$59.29+30.1%-15.4%$2.52B$1.25B-11.142,900Positive NewsWRBYWarby Parker2.4547 of 5 stars$21.40-3.8%$22.88+6.9%+42.1%$2.32B$771.32M-178.333,780News CoveragePositive NewsAnalyst Downgrade Related Companies and Tools Related Companies BLCO Alternatives NARI Alternatives IRTC Alternatives TMDX Alternatives SLNO Alternatives INSP Alternatives NVST Alternatives PRCT Alternatives LIVN Alternatives WRBY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CDRE) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadre Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadre With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CDRE Stock Alerts